Viking Therapeutics Surges 23%: Is VKTX the Next Obesity Blockbuster?

$VKTX just had a day. Viking Therapeutics surged more than 23% after its dual-action obesity drug showed patients could cut their dosing frequency and still keep the weight off. Bloomberg's Money Minute flagged it as the top story of the session, and honestly, the market's reaction makes sense: if you can dose less and lose the same amount, you've just solved one of the biggest compliance problems in GLP-1 land. The drug isn't just competing on efficacy anymore, it's competing on convenience.

For context, $LLY and $NVO still own this space, and Ken Langone went on CNBC predicting Eli Lilly hits $2,000 per share within three to four years as the company builds what he called a 'fortress' across multiple therapeutic areas. But Viking's data is a real shot across the bow. The GLP-1 race just got a third serious contender, and the social chatter on X is split between 'VKTX to the moon' and 'wait for the Phase 3 before you mortgage your house.' Both camps have a point.

Meanwhile, $MU is the quieter story getting serious attention from traders who actually do their homework. Brian Shannon on TraderTV Live walked through Micron's chart this morning: rising 20-day and 50-day moving averages, a clean breakout from range, and higher lows stacking up. Earnings land in 8 days, which creates both the opportunity and the risk. YouTube's swing-trading crowd is positioning long, but Shannon was clear that the upcoming print adds a coin-flip element. Smaller size, tighter stops. Classic pre-earnings setup talk, but grounded in an actual chart.

The macro backdrop helps both names. The Nasdaq ripped 2.26% on Monday and is sitting at record highs, the VIX has collapsed from 17.71 last Tuesday to 14.87, and the risk-on tone is giving speculators room to breathe. Even with the 10-year yield back above 5%, the growth-and-biotech trade is alive.

The difference between VKTX and MU right now is the difference between a catalyst that already fired and a catalyst that's eight days away. Viking holders are figuring out where to trim. Micron traders are figuring out how much to hold into the print. Neither is a passive situation, and that's exactly why both tickers are dominating the feed.

One cures obesity. One stores your AI training data. Both need your attention this week.